Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation

Clinical Analysis of Malignant Tumors in Recipients of Renal Transplantation

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

AN ONE-CENTER EPIDEMIOGRAPHIC ANALYSIS OF MALIGNANCY IN RENAL ALLOGRAFY RECIPIENTS

Long-term Survival and Risk Factors of Prognosis after Liver Transplantation for Malignant Liver Tumors

Low recurrence of preexisting extrahepatic malignancies after liver transplantation

Postoperative Recurrence of Liver Malignant Tumor after Liver Transplantation

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Recurrent rejections after liver transplantation for hepatocellular carcinoma with stem cell features in an adult patient

Genitourinary tumors and liver transplantation: A comprehensive review

Acute Myeloid Leukemia of A Primary Hepatic Carcinoma Patient after Liver Transplantation: A Case Report and Literature Review

Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation

No-touch Recipient Hepatectomy in Liver Transplantation for Liver Malignancies: A State-of-the-art Review

Liver Transplantation Using the Otherwise-Discarded Partial Liver Resection Graft with Hepatic Benign Tumor

Role of Liver Transplantation in Treatment of Liver Malignancy

Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria

The Impact of Tumor Recurrence to Long Term Survival after Liver Transplantation

Fighting malignancy in organ transplant recipients

Survival benefit of living donor liver transplant for patients with hepatocellular carcinoma

Graft‐Versus‐Tumor Effect in Major Histocompatibility Complex–Mismatched Mouse Liver Transplantation

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?